NCT07145164View on ClinicalTrials.gov

Interleukin-15 to Promote Post-ART Control of HIV

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

HIV

Interventions

DRUG

N-803

This is the active drug.

DRUG

Saline placebo

This is the placebo.

Trial Locations (1)

94044

UCSF, San Francisco

All Listed Sponsors

collaborator

amfAR, The Foundation for AIDS Research

OTHER

lead

Michael Peluso, MD

OTHER